What is more, activated CD4+ TSCM (Tc-I 32) and naïve CD4+ Tc (Tc-I 12 & Tc-I 22) were elevated in the PB of RRMS compared to glioblastoma patients (Fig. 5b–d). This evidence concerns the gene CD4 and glioblastoma.